Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: A summary of prevalence, underlying mechanisms and data limitations

CNS Drugs

Volumn 26, Issue 4, 2012, Pages 319-335

  Piedad, John ^a   Rickards, Hugh ^a   Besag, Frank M C ^b   Cavanna, Andrea E ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Twinwoods Health Resource Centre ^*  (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Aggression; Antiepileptic drugs; Anxiety; Depression; Epilepsy; Psychotic disorders; Sleep.

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CARISBAMATE; DIAZEPAM; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; LORECLEZOLE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABNORMAL THINKING; AFFECTIVE PSYCHOSIS; AGGRESSION; AGITATION; ANXIETY; BEHAVIOR CHANGE; DEPRESSION; DROWSINESS; EPILEPSY; EUPHORIA; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABILITY; MENTAL DISEASE; MENTAL INSTABILITY; MENTAL PATIENT; MOOD DISORDER; NERVOUSNESS; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TRANQUILIZING ACTIVITY;

AFFECT; ANIMALS; ANTICONVULSANTS; EPILEPSY; HUMANS; PREVALENCE; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTROPIC DRUGS; RESEARCH DESIGN; SLEEP;

EID: 84859063328     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11599780-000000000-00000     Document Type: Review

References (115)

1. White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol 2007; 81: 85-110
2. Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006; 69 (3): 273-94 (Pubitemid 44209049)
3. Wingrove PB, Wafford KA, Bain C, et al. The modulatory action of loreclezole at the gamma-aminobutyric acid type A receptor is determined by a single amino acid in the beta 2 and beta 3 subunit. Proc Nat Acad Sci U S A 1994; 91 (10): 4569-73 (Pubitemid 24143475)
4. LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004; 291 (5): 605-14 (Pubitemid 38500315)
5. Engel J, Pedley TA. Epilepsy: a comprehensive textbook. 2nd ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2008
6. Lopez-Gomez M, Ramirez-Bermudez J, Campillo C, et al. Primidone is associated with interictal depression in patients with epilepsy. Epilepsy Behav 2005; 6: 413-6 (Pubitemid 40468432)
7. Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48 (7): 1308-17 (Pubitemid 47063096)
8. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50 (3): 443-53
9. Kandel ER. Disorders of thought and volition: schizophrenia. In: Kandel ER, Schwartz JH, Jessell TM, editors. Principles of neural science. 4th ed. New York (NY): McGraw-Hill, 2000; 60: 1188-208
10. Oyebode F, Clark T. Basic psychiatric concepts. In: Richards D, Clark T, Clarke C, editors. The human brain and its disorders. New York (NY): Oxford University Press, 2007; 4: 62-83
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
12. World Health Organisation. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organisation, 1992
13. Gilliam F, Kanner AM. Treatment of depressive disorders in epilepsy. Epilepsy Behav 2002; 3 (5 Suppl. 1): S2-9
14. Moher D, Liberati A, Tetzlaff J, et al., Prisma Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6 (7): e1000097
15. Besag FM. Behavioural effects of new anticonvulsants. Drug Saf 2001; 24 (7): 513-36
16. Dam M, Ekberg R, Løyning Y, et al., Scandinavian Oxcarbazepine Study Group. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3: 70-6 (Pubitemid 19009372)
17. Berg I, Butler A, Ellis M, et al. Psychiatric aspects of epilepsy in childhood treated with carbamazepine, phenytoin or sodium valproate: a random trial. Dev Med Child Neurol 1993; 35: 149-57 (Pubitemid 23059555)
18. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy: UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345: 476-9
19. Pulliainen V, Jokelainen M. Comparing the cognitive effects of phenytoin and carbamazepine in long-term monotherapy: a two year follow up. Epilepsia 1995; 36: 1195-202
20. Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet 1999; 354: 13-9 (Pubitemid 29304296)
21. Trenité DG, French JA, Hirsch E, et al. Evaluation of carisbamate, a novel antiepileptic drug, in photosensitive patients: an exploratory, placebo-controlled study. Epilepsy Res 2007; 74: 193-200 (Pubitemid 46667226)
22. Dreifuss FE, Rosman P, Cloyd JC, et al. A comparison of rectal diazepam and placebo for acute repetitive seizures. N Engl J Med 1998; 338: 1869-75 (Pubitemid 28287858)
23. Kriel RL, Cloyd JC, Pellock JM, et al. Rectal diazepam gel for treatment of acute repetitive seizures. Pediatr Neurol 1990; 20: 282-8
24. Ketter TA, Malow BA, Flamini R, et al. Felbamate monotherapy has stimulant-like effects in patients with epilepsy. Epilepsy Res 1996; 23: 129-37 (Pubitemid 26124781)
25. Weintraub D, Buchsbaum R, Resor Jr SR, et al. Psychiatric and behavioural side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav 2007; 10: 105-10 (Pubitemid 46132156)
26. Crawford P, Ghadiali E, Lane R, et al. Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry 1987; 50: 682-6 (Pubitemid 17076278)
27. Chadwick D, Leiderman DB, Sauermann W, et al. Gabapentin in generalized seizures. Epilepsy Res 1996; 25: 191-7 (Pubitemid 26394540)
28. Dimond KR, Pande AC, Moreaux L, et al. Effect of gabapentin (Neurotonin) on mood and well-being in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 407-17 (Pubitemid 26168820)
29. Harden CL, Lazar LM, Pick LH, et al. Beneficial effect on mood in partial epilepsy patients treated with gabapentin. Epilepsia 1999; 40: 1129-34 (Pubitemid 29372629)
30. Biton V, Rosenfeld WE, Whitesides J, et al. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008; 49 (3): 418-24 (Pubitemid 351294527)
31. Gilliam F, Vazquez B, Sackellares JC, et al. An active control trial of lamotrigine monotherapy for partial seizures. Neurology 1998; 51: 1018-25 (Pubitemid 28473394)
32. Sadler M. Lamotrigine associated with insomnia. Epilepsia 1999; 40 (3): 322-5 (Pubitemid 29164797)
33. Parmeggiani L, Belmonte A, Ferrarri AR, et al. Add-on lamotrigine treatment in children and young adults with severe partial epilepsy: an open, prospective, long-term study. J Child Neurol 2000; 15: 671-4
34. Edwards KR, Sackellares JC, Vuong A, et al. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy Behav 2001; 2: 28-36 (Pubitemid 33585768)
35. Biton V, Levisohn P, Hoyler S, et al. Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J Child Neurol 2003; 18: 133-9 (Pubitemid 36432344)
36. Cramer JA, Hammer AE, Kustra RP. Quality of life improvement with conversion to lamotrigine monotherapy. Epilepsy Behav 2004; 5: 224-30 (Pubitemid 38461212)
37. Cramer JA, Hammer AE, Kustra RP. Improved mood states with lamotrigine in patients with epilepsy. Epilepsy Behav 2004; 5: 702-7 (Pubitemid 40392587)
38. Ettinger AB, Kustra RP, Hammer AE. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy Behav 2007; 10: 148-54 (Pubitemid 46132163)
39. Fakhoury TA, Miller JM, Hammer AE, et al. Effects of lamotrigine on mood in older adults with epilepsy and comorbid depressive symptoms: an open-label, multicentre, prospective study. Drugs Aging 2008; 25 (11): 955-62
40. Kalogjera-Sackellares D, Sackellares JC. Improvement in depression associated with partial epilepsy in patients treated with lamotrigine. Epilepsy Behav 2002; 3: 510-6 (Pubitemid 37098511)
41. Labiner DM, Ettinger AB, Fakhoury TA, et al. Effects of lamotrigine compared with levetiracetam on anger, hostility and total mood in patients with partial epilepsy. Epilepsia 2009; 50 (3): 434-42
42. Kwan P, Brodie MJ, Kälviänen R, et al. Efficacy and safety of pregabalin in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol 2011; 10: 881-90
43. Cramer JA, Arrigo C, van Hammeé G, et al. Effect of levetiracetam on epilepsy-related quality of life. Epilepsia 2000; 41: 868-74 (Pubitemid 30439579)
44. Ben-Menachem E, Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 2003; 12: 131-5 (Pubitemid 36443006)
45. Betts T, Yarrow H, Greenhill L, et al. Clinical experience of marketed levetiracetam in an epilepsy clinic: a one year follow up study. Seizure 2003; 12: 136-40 (Pubitemid 36443007)
46. Cramer JA, de Rue K, Devisnky O, et al. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003; 4: 123-32
47. Mula M, Trimble MR, Yuen A, et al. Psychiatric adverse events during levetiracetam therapy. Neurology 2003; 61: 704-6 (Pubitemid 37082613)
48. Mula M, Trimbl MR, Sander JWAS. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure 2004; 13: 55-7 (Pubitemid 38139666)
49. Opp J, Tuxhorn I, May T, et al. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Seizure 2005; 14: 476-84 (Pubitemid 41548603)
50. Mazza M, Martini A, Scoppetta M, et al. Effect of levetiracetam on depression and anxiety in adult epileptic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007; 32: 539-43
51. de la Loge C, Hunter SJ, Schiemann J, et al. Assessment of behavioural and emotional functioning using standardized instruments in children and adolescents with partialonset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial. Epilepsy Behav 2010; 18: 291-8
52. Levisohn PM, Mintz M, Hunter SJ, et al., N01103 Levetiracetam Study Group. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. Epilepsia 2009; 50 (11): 2377-89
53. Rentmeester T, Janssen A, Hulsman J, et al. A double-blind, placebo-controlled evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures. Epilepsy Res 1991; 9: 59-69
54. McKee PJW, Blackclaw J, Forrest G, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 1994; 37: 27-32 (Pubitemid 24204577)
55. Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999; 52 (4): 732-7 (Pubitemid 29120175)
56. Mazza M, Della Marca G, Di Nicola M, et al. Oxcarbazepine improves mood in patients with epilepsy. Epilepsy Behav 2007; 10: 397-401 (Pubitemid 46567766)
57. Thilothammal N, Banu K, Ratnam RS. Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double-blind study. Indian Pediatr 1996; 33 (7): 549-55 (Pubitemid 26245861)
58. Dodrill CB, Arnett JL, Shu V, et al. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998; 39: 33-42 (Pubitemid 28116839)
59. Trimble MR, Rüsch N, Betts T, et al. Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables. Seizure 2000; 9: 249-54 (Pubitemid 30427132)
60. Sackellares JC, Krauss G, Sommerville KW, et al. Occurrence of psychosis in patients with epilepsy randomized to tiagabine or placebo treatment. Epilepsia 2002; 43 (4): 394-8 (Pubitemid 34297177)
61. Elterman RD, Glauser TA, Wylie E, et al. A double-blind, randomised trial of topiramate as adjunctive therapy for partial-onset seizures in children: Topiramate YP Study Group. Neurology 1999; 52 (7): 1338-44 (Pubitemid 29190521)
62. Khan A, Fraught E, Gilliam F, et al. Acute psychotic symptoms induced by topiramate. Seizure 1999; 8: 235-7 (Pubitemid 29401589)
63. Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome: Topiramate YL Study Group. Neurology 1999; 52 (9): 1882-7 (Pubitemid 29260904)
64. Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000; 41 (9): 1167-78
65. Guberman A, Neto W, Gassmann-Mayer C, EPAJ-119 Study Group. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand 2002; 106: 183-9
66. Christensen J, Andreasen F, Poulsen JH, et al. Randomized, concentration-controlled trial of topiramate in refractory focal epilepsy. Neurology 2003; 61: 1210-8 (Pubitemid 37377539)
67. Kanner AM, Wuu J, Faught E, et al. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 2003; 4: 548-52
68. Mula M, Trimble MR, Lhatoo SD, et al. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003; 44: 659-93
69. Grošelj J, Guerrini R, van Oene J, et al. Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy. Acta Neurol Scand 2005; 122: 144-50 (Pubitemid 41153044)
70. Richens A, Ahmad S. Controlled trial of sodium valproate in severe epilepsy. Br Med J 1975; 4: 255-6
71. Dodrill CB, Arnett JL, Sommerville KW, et al. Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia 1995; 36: 164-73
72. Wong I. Retrospective study of vigabatrin and psychiatric behavioural disturbances. Epilepsy Res 1995; 21: 227-30
73. Levinson DF, Devinsky O. Psychiatric events during vigabatrin therapy. Neurology 1999; 53: 1503-11
74. Veggiotti P, de Agostini G, Muzio C, et al. Vigabatrin use in psychotic epileptic patients: report of a prospective pilot study. Acta Neurol Scand 1999; 99: 132-46
75. Guberman A, Bruni J. Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. Seizure 2000; 9: 112-8 (Pubitemid 30209799)
76. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for addon treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993; 15: 67-73 (Pubitemid 23152402)
77. Faught E, Ayala R, Montouris GG, et al., Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001; 57: 1774-9 (Pubitemid 33096682)
78. Quay H. Classification. In: Quay HC, Werry JS, editors. Psychopathological disorders of childhood. 2nd ed. Chichester: John Wiley, 1979; 1-42
79. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-71
80. Beck AT, Steer RA, Brown GK. Manual for the Beck Depression Inventory-II. San Antonio (TX): Psychological Corporation, 1996
81. Bunney WE, Hamburg DA. Methods for reliable longitudinal observation of behaviour. Arch Gen Psychiatry 1963; 9: 280-94
82. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in and scaling. Psychopharmacol Bull 1988; 24: 97-9
83. Achenbach TM, Rescorla LA. Manual for ASEBA school-age forms and profiles. Burlington (VT): University of Vermont, Research Center for Children, Youth, and Families, 2001
84. Mason BJ, Kocsis JH, Leon AC. Measurement of severity and treatment response in dysthymia. Ann Gen Psychiatry 1993; 23: 625-31
85. Radloff L. The CES-D Scale: a self-report depression measure for research in the general population. Appl Psychol Meas 1977; 1: 385-401
86. Guy W. The Clinical Global Impression (CGI) scale. In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Rockville (MD): U.S. Department of Health, Education and Welfare, 1976: 218-22
87. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991; 14: 540-5
88. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70 (Pubitemid 13098606)
89. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-5
90. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
91. Snaith RP, Constantopolous AA, Jardine MY, et al. A clinical scale for the self-assessment of irritability. Br J Psychiatry 1978; 132: 164-71 (Pubitemid 8264223)
92. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9 (Pubitemid 9136500)
93. Hathaway SR, Mckinley JC. A multiphasic personality schedule (Minnesota): I. Construction of the schedule. J Psychol 1940; 10: 249-54
94. Dodrill CB. Behavioural effects of antiepileptic drugs. In: Smith D, Treiman D, Trimble MR, editors. Neurobehavioural problems in epilepsy. New York (NY): Raven Press, 1991: 213-24
95. Gilliam FG, Barry JJ, Hermann BP, et al. Rapid detection of major depression in epilepsy: a multicenter study. Lancet Neurol 2006; 5: 399-405
96. McNair DM, Lorr M, Droppleman LF. Manual for the profile of mood states. San Diego (CA): Educational and Industrial Testing Services, 1971
97. Cramer JA, Perrine K, Devinsky O, et al. Development and cross-cultural translation of a 31-item quality of life questionnaire (QOLIE-31). Epilepsia 1998; 39: 81-8 (Pubitemid 28116846)
98. Spielberger CD, Gorsuch RL, Luschene RE. Manual for the State-Trait Anxiety Inventory (STAI Form Y). Palo Alto (CA): Consulting Psychologists Press, 1983
99. Spielberger CD, Johnson EH, Russell SF, et al. The experience and expression of anger: construction and validation of an anger expression scale. In: Chesney MA, Rosenman RH, editors. Anger and hostility in cardiovascular and behavioral disorders. New York (NY): Hemisphere/McGraw-Hill, 1985: 5-30
100. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-9
101. World Health Organisation Collaborating Centre for International Drug Monitoring. The WHO adverse reaction terminology: WHO-ART [online]. Available from URL: http://www.umc-products.com/graphics/3149.pdf [Accessed 2009 Apr 2]
102. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-35 (Pubitemid 9006756)
103. Zung WW. A rating instrument for anxiety disorders. Psychosomatics 1971; 12: 371-9
104. Zung WW. A self-rating depression scale. Arch Gen Psychiatry 1965; 12: 63-70
105. Schmitz B. Psychiatric syndromes related to antiepileptic drugs. Epilepsia 1999; 40 Suppl. 10: S65-70
106. Altshuler D, Daly MJ, Lander ES. Genetic mapping in human disease. Science 2008; 322: 881-8
107. Ettinger AB. Psychotropic effects of antiepileptic drugs. Neurology 2006; 67: 1916-25 (Pubitemid 44967364)
108. Nadkarni S, Devinsky O. Psychotropic effects of antiepileptic drugs. Epilepsy Curr 2005; 5: 176-81
109. Trimble MR. Overview: psychiatric issues. In: Engel J, Pedley TA, editors. Epilepsy: a comprehensive textbook. 2nd ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2008; 3: 2075-6
110. Mula M, Trimble MR, Sander JW. Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. Epilepsia 2007; 48: 2322-6 (Pubitemid 350243412)
111. Kanner A. Can antiepileptic drugs unmask a susceptibility to psychiatric disorders? Nat Clin Practice Neurol 2009; 5 (3): 132-3
112. Kanner AM. Depression and epilepsy: a bidirectional relation? Epilepsia 2011; 52 Suppl. 1: 21-7
113. Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in seizure disorders. Neurology 1999; 53 (5 Suppl. 2): S53-67 (Pubitemid 29442167)
114. Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment resistant depression. Neuron 2005; 45: 651-60 (Pubitemid 40320700)
115. Cramer JA, Brandenburg NA, Xu X, et al. The impact of seizures and adverse effects on global health ratings. Epilepsy Behav 2007; 11: 179-84 (Pubitemid 47279105)